

Amendment

Please amend the claims as follows:

Please cancel claims 16-26, 34-39, 60, 69, 75-78
and 79-82, all claims currently pending.

Please add the following claims:

Subc1
83. A transgenic nonprimate mammal comprising in its germline a modified genome wherein said modification comprises a lesion in the J region of at least one copy of the immunoglobulin heavy chain locus, wherein said lesion results in the inability of said copy of the locus to rearrange or to produce a functional message encoding an immunoglobulin heavy-chain subunit.

B
84. The mammal of claim 83 wherein said modification further comprises a ~~lesion~~ *deletion* in the J or constant region or both of at least one copy of an immunoglobulin light-chain locus, said ~~lesion~~ *deletion* resulting in the inability of said locus to rearrange or to produce a functional message encoding said light-chain subunit.

sl
E1
85. The mammal of claim 83 wherein said modification comprises said ~~lesions~~ *deletion* in two copies of the immunoglobulin heavy-chain locus or further comprises said ~~lesions~~ *deletion* in two copies of said immunoglobulin light-chain locus or both.

86. The mammal of claim 83 wherein said modification further comprises inclusion of, in said genome,

an immunoglobulin locus encoding a xenogeneic light chain or xenogeneic heavy chain or both.

87. The mammal of claim 84 wherein said modification further comprises inclusion of, in said genome, an immunoglobulin locus encoding a xenogeneic light chain or xenogeneic heavy chain or both.

88. The mammal of claim 85 wherein said modification further comprises inclusion of, in said genome, an immunoglobulin locus encoding a xenogeneic light chain or xenogeneic heavy chain or both.

89. The transgenic nonprimate mammal of claim 83 which is a mouse.

90. The transgenic nonprimate mammal of claim 84 which is a mouse.

91. The transgenic nonprimate mammal of claim 85 which is a mouse.

92. The transgenic nonprimate mammal of claim 86 which is a mouse.

93. The transgenic nonprimate mammal of claim 87 which is a mouse.

94. The transgenic nonprimate mammal of claim 88 which is a mouse.

6, 104

95. The transgenic nonprimate mammal of claim 86
wherein the xenogeneic immunoglobulin locus is human.

96. The transgenic nonprimate mammal of claim 87
wherein the xenogeneic immunoglobulin locus is human.

97. The transgenic nonprimate mammal of claim 88
wherein the xenogeneic immunoglobulin locus is human.

98. The transgenic nonprimate mammal of claim 89
wherein the xenogeneic immunoglobulin locus is human.

99. The transgenic nonprimate mammal of claim 90
wherein the xenogeneic immunoglobulin locus is human.

100. The transgenic nonprimate mammal of claim 91
wherein the xenogeneic immunoglobulin locus is human.

101. The transgenic nonprimate mammal of claim 92
wherein the xenogeneic immunoglobulin locus is human.

102. The transgenic nonprimate mammal of claim 93
wherein the xenogeneic immunoglobulin locus is human.

103. The transgenic nonprimate mammal of claim 94
wherein the xenogeneic immunoglobulin locus is human.

Remarks

The claims have been amended in order more particularly to point out the invention and in response to the objections raised under 35 U.S.C. § 112. The claims as now outlined focus on the clearly inventive step of

15